What is Swixx BioPharma?
Swixx BioPharma operates as a dedicated agent for ethical pharmaceuticals, catering to research-based biopharmaceutical entities across Central and Eastern Europe (CEE). With its corporate headquarters situated in Baar, Switzerland, the company plays a crucial role in facilitating access to vital pharmaceutical agents for the region's research and development ecosystem. Its focus on ethical distribution and serving research-intensive biopharma clients positions it as a key partner in advancing medical science and therapeutic innovation.
How much funding has Swixx BioPharma raised?
Swixx BioPharma has raised a total of $21.8M across 1 funding round:
Private Equity
$21.8M
Private Equity (2017): $21.8M with participation from HBM Healthcare
Key Investors in Swixx BioPharma
HBM Healthcare
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market, driven by demographic trends, medical advancements, and increasing demand for innovative therapies.
What's next for Swixx BioPharma?
The substantial enterprise-level funding, including the recent strategic investment, positions Swixx BioPharma for accelerated growth and enhanced service capabilities. This capital injection is expected to fuel strategic initiatives, potentially involving the expansion of its pharmaceutical agent portfolio, strengthening its distribution network within CEE, and investing in advanced logistical solutions. The company's focus on ethical pharmaceuticals for research-based biopharma suggests a continued commitment to supporting cutting-edge drug development and clinical trials, further solidifying its role as a vital link in the pharmaceutical value chain.
See full Swixx BioPharma company page
